Myleran is a chemotherapy drug licensed for the treatment of a certain type of cancer known as chronic myelogenous leukemia. This prescription medicine comes in tablet form and is taken once a day. It works by preventing cancer cells from growing and multiplying. Most people using this drug will develop some type of reaction, such as infections, anemia, or bleeding.
Myleran® (busulfan) is a prescription medication approved to treat chronic myelogenous leukemia, a type of cancer of the blood cells. Chronic myelogenous leukemia is also called chronic myeloid leukemia or chronic granulocytic leukemia. Myleran belongs to a group of chemotherapy medicines known as alkylating agents.
Myleran is manufactured by Excella GmbH for Aspen Global Incorporated and distributed by Prasco Laboratories.
Myleran is part of a group of medications called alkylating agents. In general, alkylating agents work by causing strands of DNA to bond to each other and become linked (this is known as "cross-linking"). The linked strands cannot uncoil and separate, which is necessary for the DNA to replicate. Because DNA replication is essential for cells to grow and multiply, alkylating agents like Myleran prevent cell growth and multiplication, and may cause cell death.